NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Sees Significant Decline in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 500 shares, a decrease of 28.6% from the September 15th total of 700 shares. Based on an average daily volume of 1,800 shares, the short-interest ratio is presently 0.3 days.

NeuroSense Therapeutics Stock Performance

NeuroSense Therapeutics stock remained flat at $0.12 during midday trading on Friday. 7 shares of the company were exchanged, compared to its average volume of 8,805. NeuroSense Therapeutics has a 1 year low of $0.07 and a 1 year high of $0.65. The firm has a fifty day moving average of $0.16 and a two-hundred day moving average of $0.20.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.